Skip to main content
Premium Trial:

Request an Annual Quote

Robert Millman, Elizabeth Stoner

Premium
Life science-investment firm MPM Capital said last week that Robert Millman and Elizabeth Stoner have joined as executive partners in MPM’s Boston office.
 
Millman was most recently chief IP counsel for Alnylam Pharmaceuticals. Prior to Alnylam, he served as the chief IP counsel at Infinity Pharmaceuticals for three years. From 1999 to 2002, Millman was chief IP counsel at Celera Genomics. Prior to that, he was patent counsel at Millennium Pharmaceuticals, an associate at Morrison and Foerster, and a patent agent at Sterne, Kessler Goldstein & Fox.
 
Millman received a JD from the Washington College of Law at American University, an MS in genetics from Washington State University, and a BS in biochemistry from the University of California, Riverside.
 
Stoner joins MPM after 22 years at Merck Research Laboratories, where she most recently served as senior vice president of global clinical development operations. Prior to Merck, she was an assistant professor of pediatrics at Cornell University Medical College.
 
Stoner received a BS in chemistry from Ottawa University, Kansas; an MS in chemistry from the State University of New York at Stony Brook, and an MD from Albert Einstein College of Medicine.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.